Evaluation of airway and circulating inflammatory biomarkers for cystic fibrosis drug development.

ABSTRACT:

Introduction

Biomarkers of inflammation in blood and sputum can play a critical role in anti-inflammatory drug development in cystic fibrosis (CF). The objectives of this analysis were to examine relationships between airway and systemic measurements of inflammation, associations between inflammatory biomarkers and FEV₁, differences in airway and systemic inflammation by baseline covariates, reproducibility of serum biomarkers, and to assess the effects of freezing and delayed processing on sputum analyte measurements.

Methods

We analyzed baseline and serial concentrations of inflammatory markers in blood and induced sputum collected from individuals with CF ages 10 years and older who participated in a multicenter clinical trial.

Results

Among circulating

SUBMITTER: Jain R 

PROVIDER: S-EPMC7775291 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature